bulleyaconitine a has been researched along with Asthma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, J; He, N; Liu, L; Sun, Y; Wang, S; Xing, H | 1 |
| Feng, Y; Jiang, Y; Sun, T; Tang, X; Xi, Y; Zhan, X; Zhang, W | 1 |
2 other study(ies) available for bulleyaconitine a and Asthma
| Article | Year |
|---|---|
Bulleyaconitine A inhibits the lung inflammation and airway remodeling through restoring Th1/Th2 balance in asthmatic model mice.
Topics: Aconitine; Airway Remodeling; Animals; Asthma; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Female; Immunoglobulin E; Interleukin-17; Mice; Mice, Inbred BALB C; Ovalbumin; Pneumonia; Signal Transduction; Th1 Cells; Th1-Th2 Balance; Th2 Cells; Treatment Outcome | 2020 |
Bulleyaconitine A Effectively Relieves Allergic Lung Inflammation in a Murine Asthmatic Model.
Topics: Aconitine; Animals; Anti-Asthmatic Agents; Asthma; Bronchoalveolar Lavage Fluid; Chemokine CCL2; China; Cytokines; Disease Models, Animal; Eosinophils; Female; Inflammation; Interleukin-4; Lung; Mice; Mice, Inbred BALB C; NF-kappa B; Ovalbumin; Protein Kinase C-delta; Tumor Necrosis Factor-alpha | 2019 |